Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U02 Substudy 02C: Investigational Agents With or Without Pembrolizumab in Melanoma
NCT04303169Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2020
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of vibostolimab, gebasaxturev, mk-4830, favezelimab and tretinoin in melanoma (6 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Who Experienced an Adverse Event at 17 months, Percentage of Participants Who Discontinued Study Intervention Due to an AE at 13 months and 1 more. Started Jun 2020; status: completed.
02
Drugs
vibostolimabgebasaxturevmk-4830favezelimabtretinoin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04303169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303169.